Cost-Effectiveness of Perioperative Pembrolizumab in Locally Advanced Head and Neck Cancer

Дата публикации: 02-07-2026 00:00:00

This economic evaluation evaluates the cost-effectiveness of perioperative pembrolizumab plus standard of care (SOC) for the treatment of locally advanced head and neck squamous cell carcinoma compared with SOC alone using Canada as a case study.

Схожие новости

#	Наименование новости	Тональность	Информативность	Дата публикации
1	International Trends in Head and Neck Cancer Mortality	0	7	25-06-2026
2	Dynamic Quality-of-Life Trajectories After Head and Neck Reconstruction	0	5	25-06-2026
3	Blood Manganese and Risk of Squamous Cell Carcinomas of the Head and Neck	0	7	02-07-2026
4	Comparison of Diet and Lifestyle Program With 3 Medication Approaches for Laryngopharyngeal Reflux Disease	0	7	02-07-2026
5	Smell and Taste Disturbances Among Glucagon-Like Peptide-1 Receptor Agonist Users	0	7	25-06-2026
6	Weight Loss at a Cost—Sense and Sensibility	0	7	25-06-2026
7	Stinson: Can FIFA World Cup 2026 be Team Canada's next leap forward in soccer?	3	6	10-06-2026
8	Ladies' charity golf day at helps raise thousands for cancer support across York	5	7	20-06-2026
9	Defense Business Brief: SECARMY’s dream marketplace; USARPAC + USVs; and Quantum EOs	0	5	25-06-2026
10	From Cathcart Castle to Carnwadric WIN: Charity woven through Scottish golf	0	5	21-06-2026

Классификация: . Схожих патентов: 0. Схожих новостей: 10. Тональность: 0. Информативность: 7. Источник: jamanetwork.com.